Viridian Therapeutics
VRDNVRDN · Stock Price
Historical price data
Overview
Viridian Therapeutics is a clinical-stage biotech focused on developing novel antibody therapeutics for rare autoimmune conditions, most notably Thyroid Eye Disease (TED). The company's strategy is built on a proprietary antibody engineering platform targeting the neonatal Fc receptor (FcRn) to reduce pathogenic autoantibodies. Its lead programs, VRDN-001 and VRDN-003, are in late-stage development for TED, positioning Viridian as a key player in a market with limited treatment options. The company aims to deliver optimized therapies with potential advantages in dosing, efficacy, and safety.
Technology Platform
Proprietary antibody discovery and engineering platform focused on inhibiting the neonatal Fc receptor (FcRn) to accelerate degradation of pathogenic IgG autoantibodies, with applications across multiple rare autoimmune conditions.
Pipeline
8| Drug | Indication | Stage | Watch |
|---|---|---|---|
| VRDN-003 + Placebo | Thyroid Eye Disease | Phase 3 | |
| VRDN-003 + Placebo | Thyroid Eye Disease | Phase 3 | |
| VRDN-003 + Placebo | Thyroid Eye Disease (TED) | Phase 3 | |
| VRDN-001 Phase 3 Cohort (THRIVE) + VRDN-001 Placebo | Thyroid Eye Disease | Phase 3 | |
| Intervention/Treatment | Thyroid Eye Disease | Phase 3 |
Opportunities
Risk Factors
Competitive Landscape
In TED, Viridian faces dominant competition from Amgen's Tepezza and emerging rivals like Immunovant. Its competitive edge relies on superior dosing convenience (subcutaneous, less frequent). In the broader FcRn space, it competes with approved therapies (Argenx's Vyvgart) and numerous late-stage programs from large pharma, requiring clear differentiation through antibody engineering.